USV launches semaglutide ‘usema’ in India 

Key Highlights: 

• USV Private, in collaboration with Dr. Reddy’s Laboratories, has launched usema in India, one of the first DCGI-approved injectable semaglutide therapies for type 2 diabetes and associated metabolic conditions. The launch targets India’s growing diabetes burden, impacting over 100M people 

• Manufactured in India, usema is designed to be bioequivalent to the innovator molecule and is supported by integrated manufacturing and cold-chain capabilities. With established safety and efficacy, the therapy aims to expand access to advanced GLP-1 treatments, reinforcing USV’s focus on affordable, high-quality metabolic care 

• The launch strengthens USV’s diabetes portfolio alongside key brands like Ecosprin and Glycomet, while complementing its broader strategy across cardiometabolic and wellness segments. Backed by collaborations and recent expansion into nutraceuticals, USV continues to deepen its presence in next-generation diabetes care in India 

Implications: 

Usema adds another early DCGI‑approved semaglutide brand to India’s GLP‑1 wave, giving USV a bioequivalent, locally manufactured injectable that fits neatly into its cardiometabolic portfolio and can be co‑detailed alongside Ecosprin and Glycomet in diabetology clinics. 
The Dr. Reddy’s collaboration plus integrated API‑to‑finished‑dose and cold‑chain capabilities should support reliable supply and quality, positioning usema as a higher‑priced but brand‑trust‑oriented option amid an increasingly crowded, aggressively priced GLP‑1 market. 

Source:  Express Pharma